8-K: Ayurcann Holdings Corp. Announces Business Combination with Arogo Capital Acquisition Corp.

Ayurcann Holdings Corp., a Canadian cannabis extraction company, is set to merge with Arogo Capital Acquisition Corp. in a deal valuing the combined entity at approximately $210 million.

Summary

• Ayurcann Holdings Corp., a Canadian cannabis extraction company, has agreed to a business combination with Arogo Capital Acquisition Corp.
• The combined entity is estimated to have an enterprise value of $210 million.
• Ayurcann is a leading producer of vapes in Ontario and a top 5 pre-roll manufacturer by volume in Ontario.
• The Canadian cannabis market is projected to reach $5.63 billion in 2024, with an expected annual growth rate of 3.17% through 2029.
• Upon completion of the merger, Ayurcann is expected to have up to $19.6 million in cash on its balance sheet, assuming no redemptions by Arogo's public stockholders.
• The transaction is expected to close in the second half of 2024, pending regulatory, court, and shareholder approvals.
• Ayurcann's revenue has grown 100% year-over-year over the last three audited financial reporting years.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth metrics and a clear path for future expansion. The merger is expected to provide significant capital and opportunities for Ayurcann.

Positives

• Ayurcann is a market leader in the Canadian cannabis extraction and product manufacturing sector.
• The company has demonstrated strong revenue growth over the past three years.
• The merger is expected to provide Ayurcann with significant capital to support further growth and expansion.
• The transaction will allow Ayurcann to explore international opportunities.

Negatives

• The transaction is subject to various approvals and conditions, which could delay or prevent its completion.
• The combined company's cash position is dependent on the level of redemptions by Arogo's public stockholders.
• The transaction is subject to the approval of the Ontario Superior Court of Justice (Commercial List).

Risks

• The transaction is subject to regulatory, court, and shareholder approvals, which may not be obtained.
• Redemptions by Arogo's public stockholders could reduce the cash available to the combined company.
• The transaction could be delayed or terminated if closing conditions are not met.
• The combined company may face challenges in integrating operations and achieving anticipated synergies.

Future Outlook

The combined company plans to use the cash from the transaction to support general business activities, including new product development, new distribution networks, and exploring national and international acquisition opportunities.

Management Comments

• Suradech Taweesaengsakulthai, CEO of Arogo, stated that Ayurcann is one of the most innovative companies they have encountered, particularly in cannabis extraction and product development.
• Igal Sudman, CEO of Ayurcann, stated that the business combination with Arogo is their next step in growing the company nationally while allowing them to also look for international opportunities.

Industry Context

The Canadian cannabis market is projected to reach $5.63 billion in 2024, indicating a strong and growing industry for Ayurcann to operate in.

Comparison to Industry Standards

• Ayurcann is the #1 producer of vapes in Ontario, demonstrating a strong market position compared to competitors.
• Ayurcann is a top 5 pre-roll manufacturer by volume in Ontario, indicating a significant market share.
• The company's 100% year-over-year revenue growth over the last three audited financial reporting years is a strong performance compared to industry averages.

Stakeholder Impact

• Shareholders of Ayurcann will receive shares of the publicly traded entity.
• Arogo's stockholders will vote on the proposed transaction.
• The combined company is expected to benefit from increased capital and market opportunities.

Next Steps

• Ayurcann will hold a special meeting of shareholders to approve the transaction.
• Arogo will file a registration statement with the SEC and mail a proxy statement/prospectus to its stockholders.
• The transaction is expected to close in the second half of 2024, subject to approvals and closing conditions.

Key Dates

Keywords

cannabis, extraction, merger, acquisition, business combination, Arogo Capital, Ayurcann, SPAC, vapes, pre-rolls, Ontario, Canada